Bayer grows Asian diabetes care business:
This article was originally published in Clinica
Bayer HealthCare is adding two new blood glucose management systems, Breeze and Brio, to its offerings in China and Korea in a bid to capitalise on the growing, and yet underpenetrated, diabetes care market in Asia. The company (part of the German drugs giant Bayer) will also be conducting information campaigns in both countries to educate people about the value of better diabetes management through regular blood glucose monitoring, diet, exercise and medication. The number of new diabetes cases in Asia is expected to more than double by 2025, according to the International Diabetes Federation. Of the 40 million in China suffering from the disorder, only 2% own a blood glucose meter for regular monitoring of their blood glucose level.
You may also be interested in...
Unilever North America agrees SmartyPant, founded in 2011 to create a comprehensive supplement made from premium ingredients to support the wellbeing needs of children and adults. Kind, fully owned by Mars, has an agreement to acquire family-owned Nature's Bakery which offers snacks including fig bars and other soft-baked foods.
Arcadia prohibited from arguing against Advantice’s appeal of National Advertising Division decision that Kerasal Fungal Nail Renewal ad claims weren’t supported. Arcadia violated confidentiality rule by publicizing NAD decision before the review was officially closed.
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.